Dr. Szilard Voros, CEO and co-founder of Global Genomics Group (G3), is currently heading the international GLOBAL study, which will enroll up to 10,000 patients with coronary artery disease. The coronary atherosclerotic disease of each patient will be precisely phenotyped with advanced CT angiography; subsequently, each patient’s blood sample will undergo a panomic analysis that includes genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, lipoprotein and proteomics. The trillions of data points collected from the phenotyping and the panomic analyses will be analyzed with specially designed bioinformatics techniques to identify novel pathways and factors contributing to atherosclerosis. We had a chance to speak with Dr. Voros about the project and what led to its development.

Read the full article here: http://www.medgadget.com/2014/02/interview-with-dr-szilard-voros-ceo-and-co-founder-of-global-genomics-group.html